Organon & Co. Financing Cash Flow
Organon & Co. (OGN) reported Financing Cash Flow of -$50.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-07-31
- Organon & Co. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$12.00M.
- Organon & Co. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$38.00M.
- Organon & Co. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$187.00M.
- Organon & Co. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$76.00M.
- Organon & Co. net cash provided by (used in) financing activities for fiscal 2025 was -$561.00M.
- Organon & Co. net cash provided by (used in) financing activities for fiscal 2024 was -$368.00M.
- Organon & Co. net cash provided by (used in) financing activities for fiscal 2023 was -$569.00M.
- Organon & Co. net cash provided by (used in) financing activities for fiscal 2022 was -$433.00M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$12.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | -$50.00M 10-Q · filed 2026-07-31 | -$237.00M derived: sum of 3 quarters · filed 2026-07-31 | -$313.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | -$38.00M 10-Q · filed 2026-05-04 | -$225.00M derived: sum of 2 quarters · filed 2026-05-04 | -$301.00M derived: sum of 3 quarters · filed 2026-05-04 | -$524.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | -$187.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$263.00M derived: sum of 2 quarters · filed 2026-02-24 | -$486.00M derived: sum of 3 quarters · filed 2026-07-31 | -$561.00M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$76.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$299.00M derived: sum of 2 quarters · filed 2026-07-31 | -$374.00M 10-Q · filed 2025-11-10 | -$456.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | -$223.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | -$298.00M 10-Q · filed 2026-07-31 | -$380.00M derived: sum of 3 quarters · filed 2026-07-31 | -$458.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | -$75.00M 10-Q · filed 2026-05-04 | -$157.00M derived: sum of 2 quarters · filed 2026-05-04 | -$235.00M derived: sum of 3 quarters · filed 2026-05-04 | -$369.00M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | -$82.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$160.00M derived: sum of 2 quarters · filed 2026-02-24 | -$294.00M derived: sum of 3 quarters · filed 2026-02-24 | -$368.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$78.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$212.00M derived: sum of 2 quarters · filed 2025-11-10 | -$286.00M 10-Q · filed 2025-11-10 | -$363.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$134.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$208.00M 10-Q · filed 2025-08-06 | -$285.00M derived: sum of 3 quarters · filed 2026-02-24 | -$363.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$74.00M 10-Q · filed 2025-05-02 | -$151.00M derived: sum of 2 quarters · filed 2026-02-24 | -$229.00M derived: sum of 3 quarters · filed 2026-02-24 | -$317.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | -$77.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$155.00M derived: sum of 2 quarters · filed 2026-02-24 | -$243.00M derived: sum of 3 quarters · filed 2026-02-24 | -$569.00M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$78.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | -$166.00M derived: sum of 2 quarters · filed 2024-11-01 | -$492.00M 10-Q · filed 2024-11-01 | -$574.00M derived: sum of 4 quarters · filed 2025-11-10 |
| 2023-06-30 | -$88.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$414.00M 10-Q · filed 2024-08-07 | -$496.00M derived: sum of 3 quarters · filed 2025-11-10 | -$573.00M derived: sum of 4 quarters · filed 2025-11-10 |
| 2023-03-31 | -$326.00M 10-Q · filed 2024-05-03 | -$408.00M derived: sum of 2 quarters · filed 2025-11-10 | -$485.00M derived: sum of 3 quarters · filed 2025-11-10 | -$668.00M derived: sum of 4 quarters · filed 2025-11-10 |
| 2022-12-31 | -$82.00M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-11-10 | -$159.00M derived: sum of 2 quarters · filed 2025-11-10 | -$342.00M derived: sum of 3 quarters · filed 2025-11-10 | -$433.00M 10-K/A · filed 2025-11-10 |
| 2022-09-30 | -$77.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$260.00M derived: sum of 2 quarters · filed 2023-11-03 | -$351.00M 10-Q · filed 2023-11-03 | |
| 2022-06-30 | -$183.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$274.00M 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | -$91.00M 10-Q · filed 2023-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |